Exact Mass: 631.3580954
Exact Mass Matches: 631.3580954
Found 214 metabolites which its exact mass value is equals to given mass value 631.3580954,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0)
PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
(32S,6S)-6-benzyl-31-[N-(N,N-dimethyl-L-leucyl)-L-isoleucyl]-(32rH,33tH)-2-oxa-5,8-diaza-1(1,4)-benzena-3(3,2)-pyrrolidina-cyclodecaphan-9c-ene-4,7-dione|Amphibin C|amphibine-C
C36H49N5O5 (631.3733503999999)
(32S,6S)-6-(S)-sec-butyl-31-[N-(N,N-dimethyl-L-phenylalanyl)-L-isoleucyl]-(32rH,33tH)-2-oxa-5,8-diaza-1(1,4)-benzena-3(3,2)-pyrrolidina-cyclodecaphan-9c-ene-4,7-dione|Amphibin D|amphibine-D
C36H49N5O5 (631.3733503999999)
(25S)-16alpha-acetoxy-3beta-beta-D-glucopyranosyloxy-16,28-seco-solanida-5,22(28)-dien-24-one|Veralodinin|veralodinine
Asp Arg Arg Trp
Asp Arg Trp Arg
Asp Trp Arg Arg
Phe Phe Arg Tyr
C33H41N7O6 (631.3118165999999)
Phe Phe Tyr Arg
C33H41N7O6 (631.3118165999999)
Phe Arg Phe Tyr
C33H41N7O6 (631.3118165999999)
Phe Arg Tyr Phe
C33H41N7O6 (631.3118165999999)
Phe Tyr Phe Arg
C33H41N7O6 (631.3118165999999)
Phe Tyr Arg Phe
C33H41N7O6 (631.3118165999999)
Ile Lys Trp Trp
C34H45N7O5 (631.3481999999999)
Ile Gln Trp Trp
C33H41N7O6 (631.3118165999999)
Ile Trp Lys Trp
C34H45N7O5 (631.3481999999999)
Ile Trp Gln Trp
C33H41N7O6 (631.3118165999999)
Ile Trp Trp Lys
C34H45N7O5 (631.3481999999999)
Ile Trp Trp Gln
C33H41N7O6 (631.3118165999999)
Lys Ile Trp Trp
C34H45N7O5 (631.3481999999999)
Lys Leu Trp Trp
C34H45N7O5 (631.3481999999999)
Lys Trp Ile Trp
C34H45N7O5 (631.3481999999999)
Lys Trp Leu Trp
C34H45N7O5 (631.3481999999999)
Lys Trp Trp Ile
C34H45N7O5 (631.3481999999999)
Lys Trp Trp Leu
C34H45N7O5 (631.3481999999999)
Leu Lys Trp Trp
C34H45N7O5 (631.3481999999999)
Leu Gln Trp Trp
C33H41N7O6 (631.3118165999999)
Leu Trp Lys Trp
C34H45N7O5 (631.3481999999999)
Leu Trp Gln Trp
C33H41N7O6 (631.3118165999999)
Leu Trp Trp Lys
C34H45N7O5 (631.3481999999999)
Leu Trp Trp Gln
C33H41N7O6 (631.3118165999999)
Gln Ile Trp Trp
C33H41N7O6 (631.3118165999999)
Gln Leu Trp Trp
C33H41N7O6 (631.3118165999999)
Gln Trp Ile Trp
C33H41N7O6 (631.3118165999999)
Gln Trp Leu Trp
C33H41N7O6 (631.3118165999999)
Gln Trp Trp Ile
C33H41N7O6 (631.3118165999999)
Gln Trp Trp Leu
C33H41N7O6 (631.3118165999999)
Arg Asp Arg Trp
Arg Asp Trp Arg
Arg Phe Phe Tyr
C33H41N7O6 (631.3118165999999)
Arg Phe Tyr Phe
C33H41N7O6 (631.3118165999999)
Arg Arg Asp Trp
Arg Arg Trp Asp
Arg Trp Asp Arg
Arg Trp Arg Asp
Arg Tyr Phe Phe
C33H41N7O6 (631.3118165999999)
Trp Asp Arg Arg
Trp Ile Lys Trp
C34H45N7O5 (631.3481999999999)
Trp Ile Gln Trp
C33H41N7O6 (631.3118165999999)
Trp Ile Trp Lys
C34H45N7O5 (631.3481999999999)
Trp Ile Trp Gln
C33H41N7O6 (631.3118165999999)
Trp Lys Ile Trp
C34H45N7O5 (631.3481999999999)
Trp Lys Leu Trp
C34H45N7O5 (631.3481999999999)
Trp Lys Trp Ile
C34H45N7O5 (631.3481999999999)
Trp Lys Trp Leu
C34H45N7O5 (631.3481999999999)
Trp Leu Lys Trp
C34H45N7O5 (631.3481999999999)
Trp Leu Gln Trp
C33H41N7O6 (631.3118165999999)
Trp Leu Trp Lys
C34H45N7O5 (631.3481999999999)
Trp Leu Trp Gln
C33H41N7O6 (631.3118165999999)
Trp Gln Ile Trp
C33H41N7O6 (631.3118165999999)
Trp Gln Leu Trp
C33H41N7O6 (631.3118165999999)
Trp Gln Trp Ile
C33H41N7O6 (631.3118165999999)
Trp Gln Trp Leu
C33H41N7O6 (631.3118165999999)
Trp Arg Asp Arg
Trp Arg Arg Asp
Trp Trp Ile Lys
C34H45N7O5 (631.3481999999999)
Trp Trp Ile Gln
C33H41N7O6 (631.3118165999999)
Trp Trp Lys Ile
C34H45N7O5 (631.3481999999999)
Trp Trp Lys Leu
C34H45N7O5 (631.3481999999999)
Trp Trp Leu Lys
C34H45N7O5 (631.3481999999999)
Trp Trp Leu Gln
C33H41N7O6 (631.3118165999999)
Trp Trp Gln Ile
C33H41N7O6 (631.3118165999999)
Trp Trp Gln Leu
C33H41N7O6 (631.3118165999999)
Tyr Phe Phe Arg
C33H41N7O6 (631.3118165999999)
Tyr Phe Arg Phe
C33H41N7O6 (631.3118165999999)
Tyr Arg Phe Phe
C33H41N7O6 (631.3118165999999)
Indinavir hydrate
C36H49N5O5 (631.3733503999999)
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
(E)-(4S,6S)-6-((S)-2-{(S)-2-[(Furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid ethyl ester
soyasapogenol E 3-O-beta-glucuronate
A monocarboxylic acid anion that results from the removal of a proton from the carboxy group of soyasapogenol E 3-O-beta-glucuronide.
(2-hydroxy-3-sulfopropyl)-dimethyl-[3-[4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]propyl]azanium
C32H59N2O8S+ (631.3991914000001)
2-amino-3-[[2-decanoyloxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-decoxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-heptanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2E,6S,8Z,10E,12S,14S,15R)-3-hexyl-12,14-dihydroxy-15-methyl-6-[(1S,2R,5E,7E)-1,2,4-trihydroxy-3,5,7-trimethylnona-5,7-dienyl]-5-oxa-17-thia-19-azabicyclo[14.2.1]nonadeca-1(18),2,8,10,16(19)-pentaen-4-one
2-amino-3-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
23-(1,2-dihydroxy-3-methylpent-3-en-1-yl)-2,21,22-trihydroxy-5,7,13,20-tetramethyl-14,25-dioxa-24-azapentacyclo[22.2.2.0³,¹².0⁴,⁹.0¹³,¹⁵]octacosa-1,10-diene-26,27-dione
(3s,4r,5r,7s,9r,12s,13s,15s,20s,21r,22r,23r)-23-[(1r,2s)-1,2-dihydroxy-3-methylpent-3-en-1-yl]-2,21,22-trihydroxy-5,7,13,20-tetramethyl-14,25-dioxa-24-azapentacyclo[22.2.2.0³,¹².0⁴,⁹.0¹³,¹⁵]octacosa-1,10-diene-26,27-dione
6-(1,3-dihydroxy-2,4,6-trimethylocta-4,6-dien-1-yl)-3-hexyl-7,13,15-trihydroxy-16-methyl-5-oxa-18-thia-20-azabicyclo[15.2.1]icosa-1(19),2,9,11,17(20)-pentaen-4-one
(2s,3r)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-3-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
11-ethyl-5,14-dihydroxy-6,8,16,18-tetramethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate
9-hexyl-7,15,18-trihydroxy-19-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-2-methyl-9h,10h,12h,13h,14h,15h,16h,19h,20h,20ah-cyclopenta[i]azacyclononadecane-11,17-dione
amphibin d
C36H49N5O5 (631.3733503999999)
{"Ingredient_id": "HBIN015904","Ingredient_name": "amphibin d","Alias": "NA","Ingredient_formula": "C36H49N5O5","Ingredient_Smile": "CCC(C)C1C(=O)NC=CC2=CC=C(C=C2)OC3CCN(C3C(=O)N1)C(=O)C(C(C)CC)NC(=O)C(CC4=CC=CC=C4)N(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25581","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
amphibine D
C36H49N5O5 (631.3733503999999)
{"Ingredient_id": "HBIN015906","Ingredient_name": "amphibine D","Alias": "amphibine d","Ingredient_formula": "C36H49N5O5","Ingredient_Smile": "CCC(C)C1C(=O)NC=CC2=CC=C(C=C2)OC3CCN(C3C(=O)N1)C(=O)C(C(C)CC)NC(=O)C(CC4=CC=CC=C4)N(C)C","Ingredient_weight": "631.8","OB_score": "17.86528711","CAS_id": "38496-02-5","SymMap_id": "SMIT03945","TCMID_id": "1081","TCMSP_id": "MOL001550","TCM_ID_id": "NA","PubChem_id": "12306074","DrugBank_id": "NA"}
(2s)-n-[(2s)-1-[(7s,10s,13z)-8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-4-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
n-(1-{10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl}-3-methyl-1-oxopentan-2-yl)-2-(dimethylamino)-4-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
(2s)-n-[(2r,3r)-1-[(3r,7r,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl]-2-(dimethylamino)-3-phenylpropanimidic acid
C36H49N5O5 (631.3733503999999)
n-{1-[8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl}-2-(dimethylamino)-3-phenylpropanimidic acid
C36H49N5O5 (631.3733503999999)
(2s,3r)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2r)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-3-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
n-{1-[(13e)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl}-2-(dimethylamino)-4-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
(2s)-n-[(2r,3s)-1-[(3s,7s,10r,13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl]-2-(dimethylamino)-4-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
n-{1-[8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl}-2-(dimethylamino)-3-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
(2s)-3-{[(1r,9s,10s,12s,14e,16s,19r,20r,21s,22r)-3,9-dihydroxy-10,12,14,16,20,21,22-heptamethyl-4-oxo-23,24-dioxatetracyclo[17.3.1.1⁶,⁹.0²,⁷]tetracosa-2,5,7,14-tetraen-8-yl]sulfanyl}-2-[(1-hydroxyethylidene)amino]propanoic acid
C34H49NO8S (631.3178714000001)
n-{1-[(13z)-8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl}-2-(dimethylamino)-3-phenylpropanimidic acid
C36H49N5O5 (631.3733503999999)
(2e,6r,7s,9z,11e,13s,15s,16r)-6-[(1r,2r,3r,4e,6e)-1,3-dihydroxy-2,4,6-trimethylocta-4,6-dien-1-yl]-3-hexyl-7,13,15-trihydroxy-16-methyl-5-oxa-18-thia-20-azabicyclo[15.2.1]icosa-1(19),2,9,11,17(20)-pentaen-4-one
(1s,2r,3r,4s,5r,6s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-8,14-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 3,4-dimethoxybenzoate
(3s,6s,9r,12s,19r)-9-benzyl-3-[(2s)-butan-2-yl]-5,8,11,14,17-pentahydroxy-6-[(1r)-1-hydroxyethyl]-12-isopropyl-19-propyl-1-oxa-4,7,10,13,16-pentaazacyclononadeca-4,7,10,13,16-pentaen-2-one
(2e,6s,7s,8r,10z,12e,14r,16r,17s)-3-hexyl-7,8,14,16-tetrahydroxy-6-[(4e,6e)-3-hydroxy-4,6-dimethylocta-4,6-dien-2-yl]-17-methyl-5-oxa-19-thia-21-azabicyclo[16.2.1]henicosa-1(20),2,10,12,18(21)-pentaen-4-one
n-{1-[(13e)-8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl}-2-(dimethylamino)-3-phenylpropanimidic acid
C36H49N5O5 (631.3733503999999)
(2s,3r)-n-[(2s)-1-[(3s,7s,10s,13e)-10-[(2r)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-3-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)
(2s)-n-[(2r,3r)-1-[(3s,7s,10r,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxopentan-2-yl]-2-(dimethylamino)-3-phenylpropanimidic acid
C36H49N5O5 (631.3733503999999)
3-({3,9-dihydroxy-10,12,14,16,20,21,22-heptamethyl-4-oxo-23,24-dioxatetracyclo[17.3.1.1⁶,⁹.0²,⁷]tetracosa-2,5,7,14-tetraen-8-yl}sulfanyl)-2-[(1-hydroxyethylidene)amino]propanoic acid
C34H49NO8S (631.3178714000001)
(9r,15r,19r,20as)-9-hexyl-7,15,18-trihydroxy-19-{[(2r,4s,5r,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2-methyl-9h,10h,12h,13h,14h,15h,16h,19h,20h,20ah-cyclopenta[i]azacyclononadecane-11,17-dione
(2e,6s,8z,10e,12s,14s,15r)-3-hexyl-12,14-dihydroxy-15-methyl-6-[(1s,2r,3r,4r,5e,7e)-1,2,4-trihydroxy-3,5,7-trimethylnona-5,7-dien-1-yl]-5-oxa-17-thia-19-azabicyclo[14.2.1]nonadeca-1(18),2,8,10,16(19)-pentaen-4-one
(2s)-n-[(2s)-1-[(7s,10s,13e)-8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-2-(dimethylamino)-4-methylpentanimidic acid
C36H49N5O5 (631.3733503999999)